Personal device for testing lung functions approved by FDA

January 31, 2012

The Spiro PD has been cleared to market by FDA for the use by a patient to test lung function in children, adolescents, and adults, the product’s developer, PMD Healthcare, announced.

The Spiro PD has been cleared to market by FDA for the use by a patient to test lung function in children, adolescents, and adults, the product’s developer, PMD Healthcare, announced.

The 9-ounce personal device is the first personal spirometer that enables patients with lung diseases – those with asthma, chronic obstructive pulmonary disease, cystic fibrosis, and lung transplants – to easily and accurately monitor their lung function any time and anywhere, according to the company’s press release.

PMD Healthcare also said the Spiro PD will:

Track lung function progress and trends to help patients anticipate and prevent exacerbations and asthma attacks, and reduce expensive emergency room trips.

Help doctors evaluate if the patient’s medication is working and dosage is correct.

Allow patients to view their lung health trends in a simple graph; color-coding lets them know at a glance the severity of their condition and translate the result into a clear action plan.

Enhance medication adherence by allowing patients to set an alarm to remind them to take their medications; proprietary software provides a time stamp to show doctors that patients have been following their therapy.

Allow patients to send their lung function data to their doctor between office visits to inform them of lung health and need for treatment changes.